摘要
1型糖尿病(IDDM/T1DM)又称胰岛素依赖型糖尿病,是一种自身免疫性疾病。新近国际学术界还将其定义为重要自身免疫性疾病(IAID)中的一类。IDDM/T1DM最突出的病理生理特征是机体同时产生异常的自身体液和细胞免疫应答,最终导致胰岛β细胞损伤破坏,胰岛素分泌量绝对性减少。因此,针对IDDM/T1DM的传统主流治疗策略始终是采用胰岛素或胰岛素类似物的长期补充疗法。然而,长期使用常常会带来诸多的毒副作用尤其是低血糖反应或低血糖昏迷以及胰岛素抗性等。近年来针对其发病新机制所采用免疫抑制剂或免疫调节剂甲氨蝶呤(MTX)的临床应用备受关注,这将成为老药新用的又一重要范例。该文综述了MTX在治疗1型糖尿病方面的应用进展。
Type 1 diabetes mellitus( T1DM),also known as insulin dependent diabetes mellitus( IDDM),is classified as an autoimmune disease. Academia currently define it as one of the important autoimmune diseases( IAIDs). The most significant pathophysiological characteristics of T1 DM are the pathological humoral and cellular autoimmune response which results in damage to pancreatic β-cell and absolute reduction insulin. Thus,the mainstream traditional therapy for T1 DM has been to chronically replenish insulin or substitutes. Nevertheless,this approach may generate a number of side effects,especially hypoglycemia reaction,hypoglycemic coma and insulin resistance. In recent years,the clinical use of methotrexate( MTX) as an immunity inhibitor or regulator aiming at pathogenesis of T1 DM has received increasing attention and will become another significant case where an old drug is used for new purposes. The advances in research on MTX in T1 DM are discussed in this paper.
出处
《军事医学》
CAS
CSCD
北大核心
2015年第6期476-479,共4页
Military Medical Sciences
基金
国家高新技术研究发展计划资助项目(SQ2014SF02D00486)
关键词
Ⅰ型糖尿病
免疫调节剂
甲氨蝶呤
type 1 diabetes mellitus
immunomodulator
methotrexate